Clinical Trials Logo

Renal Interstitial Fibrosis clinical trials

View clinical trials related to Renal Interstitial Fibrosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03321942 Recruiting - Clinical trials for Chronic Kidney Diseases

Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

To investigate the biological characteristics of adipose tissue-derived mesenchymal stem cells(AMSCs) and its treatment effects on chronic renal failure.

NCT ID: NCT01079143 Completed - Clinical trials for Renal Interstitial Fibrosis

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

CERTITEM
Start date: September 2009
Phase: Phase 3
Study type: Interventional

Recently, early biomarkers of renal interstitial fibrosis have been identified, amongst them de novo expression of vimentin by tubular epithelial cells, which is an intermediate filament, and the translocation of beta-catenin into their cytoplasm. These markers, when present, suggest that the epithelial cell undergoes a phenomenon well known as "epithelial to mesenchymal transition" (EMT) and could behaves like a myo-fibroblast. EMT is highly instrumental in several models of tissue fibrosis, including in the kidney. Actually, it has not only been demonstrated that these markers are detectable in the renal graft at an early time point post-transplant (i.e. as soon as three months), but also that the intensity of their expression correlates with the progression of interstitial fibrosis of the graft between 3 and 12 months